The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: Intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation

Toxicology and Applied Pharmacology

Volumn 244, Issue 3, 2010, Pages 344-353

  Garcia Ratés, Sara ^a   Camarasa, Jordi ^a   Sánchez García, Ana I ^b   Gandía, Luis ^b   Escubedo, Elena ^a   Pubill, David ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Calcium; Ecstasy; Fluo 4; MDMA; Nicotinic acetylcholine receptors; PC12 cells; Xenopus oocytes

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; ALPHA BUNGAROTOXIN; BUNGAROTOXIN RECEPTOR; CALCIUM CHANNEL; CALCIUM ION; CALPAIN; CASPASE 3; DIHYDRO BETA ERYTHROIDINE; DOPAMINE TRANSPORTER; FODRIN; METHYLLYCACONITINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; ACETYLCHOLINE; CALCIUM; NICOTINE; NICOTINIC AGENT; SPECTRIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPHYSIOLOGY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; FLUOROMETRY; GENETIC TRANSFECTION; IC 50; NONHUMAN; OOCYTE; UPREGULATION; XENOPUS; ANIMAL; CELL STRAIN; DRUG EFFECT; HUMAN; METABOLISM; RAT;

ACETYLCHOLINE; ANIMALS; CALCIUM; CALCIUM CHANNELS; CALPAIN; CASPASE 3; ENZYME ACTIVATION; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PC12 CELLS; RATS; RECEPTORS, NICOTINIC; SPECTRIN; UP-REGULATION; XENOPUS;

EID: 77950464763     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.01.014     Document Type: Article

References (71)

1. Albuquerque E.X., Pereira E.F., Alkondon M., Rogers S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 2009, 89:73-120.
2. Alkondon M., Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I: pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 1993, 265:1455-1473.
3. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149:159-163.
4. Blumenthal E.M., Conroy W.G., Romano S.J., Kassner P.D., Berg D.K. Detection of functional nicotinic receptors blocked by alpha-bungarotoxin on PC12 cells and dependence of their expression on post-translational events. J. Neurosci. 1997, 17:6094-6104.
5. Bodnar A.L., Cortes-Burgos L.A., Cook K.K., Dinh D.M., Groppi V.E., Hajos M., Higdon N.R., Hoffmann W.E., Hurst R.S., Myers J.K., Rogers B.N., Wall T.M., Wolfe M.L., Wong E. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors. J. Med. Chem. 2005, 48:905-908.
6. 2+ release. FASEB J. 2002, 16:1145-1150.
7. Buki A., Koizumi H., Povlishock J.T. Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp. Neurol. 1999, 159:319-328.
8. Camarasa J., Marimon J.M., Rodrigo T., Escubedo E., Pubill D. Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats. Eur. J. Pharmacol. 2008, 589:132-139.
9. Campos-Caro A., Smillie F.I., Dominguez del T.E., Rovira J.C., Vicente-Agullo F., Chapuli J., Juiz J.M., Sala S., Sala F., Ballesta J.J., Criado M. Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: cloning, expression, and genomic organization of receptor subunits. J. Neurochem. 1997, 68:488-497.
10. Chipana C., Camarasa J., Pubill D., Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 2006, 51:885-895.
11. Chipana C., Garcia-Rates S., Camarasa J., Pubill D., Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem. Int. 2008, 52:401-410.
12. Chipana C., Camarasa J., Pubill D., Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 2008, 29:179-183.
13. Chipana C., Torres I., Camarasa J., Pubill D., Escubedo E. Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 2008, 54:1254-1263.
14. Criado M., Mulet J., Bernal J.A., Gerber S., Sala S., Sala F. Mutations of a conserved lysine residue in the N-terminal domain of alpha7 nicotinic receptors affect gating and binding of nicotinic agonists. Mol. Pharmacol. 2005, 68:1669-1677.
15. Dajas-Bailador F., Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci. 2004, 25:317-324.
16. Demiryurek A.T., Cakici I., Kanzik I. Peroxynitrite: a putative cytotoxin. Pharmacol. Toxicol. 1998, 82:113-117.
17. Deng X., Cadet J.L. Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res. 1999, 851:254-257.
18. Dickinson J.A., Hanrott K.E., Mok M.H., Kew J.N., Wonnacott S. Differential coupling of alpha7 and non-alpha7 nicotinic acetylcholine receptors to calcium-induced calcium release and voltage-operated calcium channels in PC12 cells. J. Neurochem. 2007, 100:1089-1096.
19. Donnellyroberts D.L., Arneric S.P., Sullivan J.P. Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium-channel antagonists. Biochem. Biophys. Res. Comm. 1995, 213:657-662.
20. Drisdel R.C., Green W.N. Neuronal alpha-bungarotoxin receptors are alpha7 subunit homomers. J. Neurosci. 2000, 20:133-139.
21. 2+-release channels. Trends Pharmacol. Sci. 1994, 15:145-149.
22. Escubedo E., Chipana C., Perez-Sanchez M., Camarasa J., Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J. Pharmacol. Exp. Ther. 2005, 315:658-667.
23. Fornai F., Lenzi P., Gesi M., Soldani P., Ferrucci M., Lazzeri G., Capobianco L., Battaglia G., de Blasi A., Nicoletti F., Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 2004, 88:114-123.
24. 2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 2004, 35:1-8.
25. Gaimarri A., Moretti M., Riganti L., Zanardi A., Clementi F., Gotti C. Regulation of neuronal nicotinic receptor traffic and expression. Brain Res. Rev. 2007, 55:134-143.
26. Garcia-Rates S., Camarasa J., Escubedo E., Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicol. Appl. Pharmacol. 2007, 223:195-205.
27. Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly-Roberts D., Arneric S.P., Bertrand D., Sullivan J.P. Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 1995, 290:237-246.
28. Gopalakrishnan M., Molinari E., Sullivan J.P. Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Mol. Pharmacol. 1997, 52:524-534.
29. Gotti C., Moretti M., Gaimarri A., Zanardi A., Clementi F., Zoli M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol. 2007, 74:1102-1111.
30. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., Fleckenstein A.E. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Ther. 2002, 300:1093-1100.
31. Harris A.S., Morrow J.S. Proteolytic processing of human brain alpha spectrin (fodrin): identification of a hypersensitive site. J. Neurosci. 1988, 8:2640-2651.
32. Henderson L.P., Gdovin M.J., Liu C., Gardner P.D., Maue R.A. Nerve growth factor increases nicotinic ACh receptor gene expression and current density in wild-type and protein kinase A-deficient PC12 cells. J. Neurosci. 1994, 14:1153-1163.
33. Hurst R.S., Hajos M., Raggenbass M., Wall T.M., Higdon N.R., Lawson J.A., Rutherford-Root K.L., Berkenpas M.B., Hoffmann W.E., Piotrowski D.W., Groppi V.E., Allaman G., Ogier R., Bertrand S., Bertrand D., Arneric S.P. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 2005, 25:4396-4405.
34. Imam S.Z., Newport G.D., Duhart H.M., Islam F., Slikker W., Ali S.F. Methamphetamine-induced dopaminergic neurotoxicity and production of peroxynitrite are potentiated in nerve growth factor differentiated pheochromocytoma 12 cells. Ann. N.Y. Acad. Sci. 2002, 965:204-213.
35. 2+ permeability in recombinant glutamate receptor subtypes. J. Physiol. 2002, 538:25-39.
36. Jimenez A., Jorda E.G., Verdaguer E., Pubill D., Sureda F.X., Canudas A.M., Escubedo E., Camarasa J., Camins A., Pallas M. Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells. Toxicol. Appl. Pharmacol. 2004, 196:223-234.
37. Johnson E.A., O'Callaghan J.P., Miller D.B. Brain concentrations of d-MDMA are increased after stress. Psychopharmacology (Berl) 2004, 173:278-286.
38. Jonnala R.R., Buccafusco J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res. 2001, 66:565-572.
39. Kawai H., Berg D.K. Nicotinic acetylcholine receptors containing alpha 7 subunits on rat cortical neurons do not undergo long-lasting inactivation even when up-regulated by chronic nicotine exposure. J. Neurochem. 2001, 78:1367-1378.
40. Kitaichi K., Morishita Y., Doi Y., Ueyama J., Matsushima M., Zhao Y.L., Takagi K., Hasegawa T. Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur. J. Pharmacol. 2003, 464:39-48.
41. Kramer H.K., Poblete J.C., Azmitia E.C. Activation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA) occurs through the stimulation of serotonin receptors and transporter. Neuropsychopharmacology 1997, 17:117-129.
42. Lyles J., Cadet J.L. Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res. Brain Res. Rev. 2003, 42:155-168.
43. Madhok T.C., Matta S.G., Sharp B.M. Nicotine regulates nicotinic cholinergic receptors and subunit mRNAs in PC 12 cells through protein kinase A. Brain Res. Mol. Brain Res. 1995, 32:143-150.
44. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl.) 2008, 200:439-450.
45. Messi M.L., Renganathan M., Grigorenko E., Delbono O. Activation of alpha7 nicotinic acetylcholine receptor promotes survival of spinal cord motoneurons. FEBS Lett. 1997, 411:32-38.
46. Metzger R.R., Hanson G.R., Gibb J.W., Fleckenstein A.E. 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur. J. Pharmacol. 1998, 349:205-210.
47. Mogg A.J., Jones F.A., Pullar I.A., Sharples C.G., Wonnacott S. Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. Neuropharmacology 2004, 47:848-859.
48. Mudo G., Belluardo N., Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J. Neural Transm. 2007, 114:135-147.
49. Nashmi R., Lester H. Cell autonomy, receptor autonomy, and thermodynamics in nicotine receptor up-regulation. Biochem. Pharmacol. 2007, 74:1145-1154.
50. Nomikos G.G., Schilstrom B., Hildebrand B.E., Panagis G., Grenhoff J., Svensson T.H. Role of alpha7 nicotinic receptors in nicotine dependence and implications for psychiatric illness. Behav. Brain Res. 2000, 113:97-103.
51. Park S.U., Ferrer J.V., Javitch J.A., Kuhn D.M. Peroxynitrite inactivates the human dopamine transporter by modification of cysteine 342: potential mechanism of neurotoxicity in dopamine neurons. J. Neurosci. 2002, 22:4399-4405.
52. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J. Psychopharmacol. 1998, 12:79-83.
53. Pauly J.R., Charriez C.M., Guseva M.V., Scheff S.W. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann. N.Y. Acad. Sci. 2004, 1035:316-334.
54. Pike B.R., Zhao X., Newcomb J.K., Posmantur R.M., Wang K.K., Hayes R.L. Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. NeuroReport 1998, 9:2437-2442.
55. Plummer M.R., Logothetis D.E., Hess P. Elementary properties and pharmacological sensitivities of calcium channels in mammalian peripheral neurons. Neuron 1989, 2:1453-1463.
56. Pubill D., Chipana C., Camins A., Pallas M., Camarasa J., Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol. 2005, 204:57-68.
57. Quednow B.B., Jessen F., Kuhn K.U., Maier W., Daum I., Wagner M. Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J. Psychopharmacol. 2006, 20:373-384.
58. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., Booij J. The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002, 26:387-396.
59. 2+ pools in neuronal signalling. Curr. Opin. Neurobiol. 2001, 11:306-311.
60. Rodgers J. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology (Berl) 2000, 151:19-24.
61. Sands S.B., Costa A.C., Patrick J.W. Barium permeability of neuronal nicotinic receptor alpha 7 expressed in Xenopus oocytes. Biophys. J. 1993, 65:2614-2621.
62. Schoffelmeer A.N., de Vries T.J., Wardeh G., van de Ven H.V., Vanderschuren L.J. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J. Neurosci. 2002, 22:3269-3276.
63. Staszewski R.D., Yamamoto B.K. Methamphetamine-induced spectrin proteolysis in the rat striatum. J. Neurochem. 2006, 96:1267-1276.
64. Sudo M., Tsuzuki K., Okado H., Miwa A., Ozawa S. Adenovirus-mediated expression of AMPA-type glutamate receptor channels in PC12 cells. Brain Res. Mol. Brain Res. 1997, 50:91-99.
65. Takahashi T., Yamashita H., Nakamura S., Ishiguro H., Nagatsu T., Kawakami H. Effects of nerve growth factor and nicotine on the expression of nicotinic acetylcholine receptor subunits in PC12 cells. Neurosci. Res. 1999, 35:175-181.
66. Trouslard J., Marsh S.J., Brown D.A. Calcium entry through nicotinic receptor channels and calcium channels in cultured rat superior cervical ganglion cells. J. Physiol. 1993, 468:53-71.
67. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci. 2000, 23:20-26.
68. Wei Q., Jurma O.P., Andersen J.K. Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells. J. Neurosci. Res. 1997, 50:618-626.
69. Yamamoto B.K., Raudensky J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol. 2008, 3:203-217.
70. Zanetti L., de Kerchove D.E., Zanardi A., Changeux J.P., Picciotto M.R., Zoli M. Inhibition of both alpha7* and beta2* nicotinic acetylcholine receptors is necessary to prevent development of sensitization to cocaine-elicited increases in extracellular dopamine levels in the ventral striatum. Psychopharmacology (Berl) 2006, 187:181-188.
71. Zhang Z., Larner S.F., Liu M.C., Zheng W., Hayes R.L., Wang K.K. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis 2009, 14:1289-1298.